Medical Developments International Limited (ASX: MVP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medical Developments International Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medical Developments International Limited (ASX: MVP)
Latest News
⏸️ Investing
Why I rate CogState Ltd shares a speculative buy
⏸️ Investing
How you can profit from 3 growing small caps revisited
⏸️ Investing
Why these 4 ASX shares pushed higher today
⏸️ Investing
Medical Developments International Ltd's Chairman sells shares, time to worry?
⏸️ Investing
3 shares I'd buy for diversification
⏸️ Investing
Medical Developments International Ltd crashes 5.4% on report
⏸️ Investing
ALL ORDINARIES finishes lower Monday: 9 shares you missed
⏸️ Investing
Medical Developments International Ltd rises 3% on Walgreens deal
⏸️ Investing
3 shares that keep giving big returns
⏸️ Investing
3 fast-growing healthcare shares to watch
⏸️ Investing
Why these 3 ASX shares just hit new all-time highs
⏸️ Investing
The Medical Developments International Ltd share price is up 55% in 2017
Frequently Asked Questions
-
Medical Developments International has not paid a Dividend since 2019.
-
Medical Developments International Ltd listed on the ASX on 15 December 2003.
MVP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Medical Developments International Limited
Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.
The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries.
